Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Influence of Modeling Choices on Value of Information Analysis: An Empirical Analysis from a Real-World Experiment.

Kim DD, Guzauskas GF, Bennette CS, Basu A, Veenstra DL, Ramsey SD, Carlson JJ.

Pharmacoeconomics. 2019 Oct 21. doi: 10.1007/s40273-019-00848-8. [Epub ahead of print]

PMID:
31631254
2.

Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug Therapy.

Guzauskas GF, Basu A, Carlson JJ, Veenstra DL.

Value Health. 2019 Sep;22(9):988-994. doi: 10.1016/j.jval.2019.03.023. Epub 2019 Aug 1.

PMID:
31511188
3.

Cost-effectiveness of population genomic screening.

Veenstra DL, Guzauskas G, Peterson J, Hassen DA, Snyder S, Hao J, Williams M.

Genet Med. 2019 Jul 15. doi: 10.1038/s41436-019-0580-4. [Epub ahead of print] No abstract available.

PMID:
31303645
4.

Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study.

Guzauskas GF, Pollom EL, Stieber VW, Wang BCM, Garrison LP Jr.

J Med Econ. 2019 Oct;22(10):1006-1013. doi: 10.1080/13696998.2019.1614933. Epub 2019 May 20.

PMID:
31050315
5.

Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States.

Guzauskas GF, Masaquel A, Thuresson PO, Dawson K, Veenstra DL.

Leuk Lymphoma. 2019 Jul;60(7):1668-1676. doi: 10.1080/10428194.2018.1551532. Epub 2019 Jan 11.

PMID:
30632837
6.

Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients.

Guzauskas GF, Salzberg M, Wang BC.

CNS Oncol. 2018 Jul 1;7(3):CNS23. doi: 10.2217/cns-2018-0010. Epub 2018 Aug 20.

7.

Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China.

Shen K, Wasserman M, Liu D, Yang YH, Yang J, Guzauskas GF, Wang BCM, Hilton B, Farkouh R.

PLoS One. 2018 Jul 25;13(7):e0201245. doi: 10.1371/journal.pone.0201245. eCollection 2018.

8.

Integrating value of research into NCI Clinical Trials Cooperative Group research review and prioritization: A pilot study.

Carlson JJ, Kim DD, Guzauskas GF, Bennette CS, Veenstra DL, Basu A, Hendrix N, Hershman DL, Baker L, Ramsey SD.

Cancer Med. 2018 Sep;7(9):4251-4260. doi: 10.1002/cam4.1657. Epub 2018 Jul 20.

9.

The Authors Respond: Reframing the Value of Treatments for Relapsed Refractory Multiple Myeloma.

Carlson JJ, Guzauskas GF, Chapman RH, Synnott PG, Liu S, Russo ET, Pearson SD, Brouwer ED, Ollendorf DA.

J Manag Care Spec Pharm. 2018 Jul;24(7):712-713. doi: 10.18553/jmcp.2018.24.7.712.

10.

Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US.

Guzauskas GF, Masaquel A, Reyes C, Bernaards C, Krivasi T, Veenstra DL.

J Med Econ. 2018 Oct;21(10):960-967. doi: 10.1080/13696998.2018.1489254. Epub 2018 Jul 6.

PMID:
29898619
11.

Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States.

Carlson JJ, Guzauskas GF, Chapman RH, Synnott PG, Liu S, Russo ET, Pearson SD, Brouwer ED, Ollendorf DA.

J Manag Care Spec Pharm. 2018 Jan;24(1):29-38. doi: 10.18553/jmcp.2018.24.1.29.

12.

Economic evaluation of telephone-based concussion management for combat-related mild traumatic brain injury.

Richardson JS, Guzauskas GF, Fann JR, Temkin NR, Bush NE, Bell KR, Gahm GA, Smolenski DJ, Brockway JA, Hansen RN.

J Telemed Telecare. 2018 May;24(4):282-289. doi: 10.1177/1357633X17696586. Epub 2017 Apr 3.

PMID:
28372513
13.

The cost-effectiveness of a NSCLC patient assistance program for pemetrexed maintenance therapy in People's Republic of China.

Shi Q, Hu S, Furnback WE, Guzauskas GF, Shen J, Wang BC.

Clinicoecon Outcomes Res. 2017 Feb 3;9:99-106. doi: 10.2147/CEOR.S119818. eCollection 2017.

14.

Are Evidence Standards Different for Genomic- vs. Clinical-Based Precision Medicine? A Quantitative Analysis of Individualized Warfarin Therapy.

Dhanda DS, Guzauskas GF, Carlson JJ, Basu A, Veenstra DL.

Clin Pharmacol Ther. 2017 Nov;102(5):805-814. doi: 10.1002/cpt.663. Epub 2017 Jul 10.

15.

What is the value of conducting a trial of r-tPA for the treatment of mild stroke patients?

Guzauskas GF, Chen E, Lalla D, Yu E, Tayama D, Veenstra DL.

Int J Stroke. 2017 Feb;12(2):137-144. doi: 10.1177/1747493016669887. Epub 2016 Oct 10.

PMID:
28134053
16.

The budget impact and cost-effectiveness of defibrotide for treatment of veno-occlusive disease with multi-organ dysfunction in patients post-hematopoietic stem cell transplant.

Veenstra DL, Guzauskas GF, Villa KF, Boudreau DM.

J Med Econ. 2017 May;20(5):453-463. doi: 10.1080/13696998.2016.1275652. Epub 2017 Jan 7.

PMID:
28008770
17.

Precision Health Economics and Outcomes Research to Support Precision Medicine: Big Data Meets Patient Heterogeneity on the Road to Value.

Chen Y, Guzauskas GF, Gu C, Wang BC, Furnback WE, Xie G, Dong P, Garrison LP.

J Pers Med. 2016 Nov 2;6(4). pii: E20.

18.

Risk-Benefit Analysis of Pediatric-Inspired Versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Protocols for Acute Lymphoblastic Leukemia in Adolescents and Young Adults.

Guzauskas GF, Villa KF, Vanhove GF, Fisher VL, Veenstra DL.

J Adolesc Young Adult Oncol. 2017 Mar;6(1):53-61. doi: 10.1089/jayao.2016.0049. Epub 2016 Oct 25.

19.

Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysis.

Serbin MA, Guzauskas GF, Veenstra DL.

J Manag Care Spec Pharm. 2016 Aug;22(8):939-47. doi: 10.18553/jmcp.2016.22.8.939. Review.

20.

The Cost-Effectiveness of Pregabalin Versus Gabapentin for Peripheral Neuropathic Pain (pNeP) and Postherpetic Neuralgia (PHN) in China.

Wang BC, Liu D, Furnback WE, Bifa F, Dong P, Xie L, Guzauskas GF, Zhang S.

Pain Ther. 2016 Jun;5(1):81-91. doi: 10.1007/s40122-016-0048-z. Epub 2016 Mar 1.

21.

Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis.

Gallego CJ, Shirts BH, Bennette CS, Guzauskas G, Amendola LM, Horike-Pyne M, Hisama FM, Pritchard CC, Grady WM, Burke W, Jarvik GP, Veenstra DL.

J Clin Oncol. 2015 Jun 20;33(18):2084-91. doi: 10.1200/JCO.2014.59.3665. Epub 2015 May 4.

22.

Cost-effectiveness of recombinant tissue-type plasminogen activator within 3 hours of acute ischemic stroke: current evidence.

Boudreau DM, Guzauskas GF, Chen E, Lalla D, Tayama D, Fagan SC, Veenstra DL.

Stroke. 2014 Oct;45(10):3032-9. doi: 10.1161/STROKEAHA.114.005852. Epub 2014 Sep 4.

PMID:
25190439
23.

Stakeholder perspectives on decision-analytic modeling frameworks to assess genetic services policy.

Guzauskas GF, Garrison LP, Stock J, Au S, Doyle DL, Veenstra DL.

Genet Med. 2013 Jan;15(1):84-7. doi: 10.1038/gim.2012.92. Epub 2012 Jul 26.

PMID:
22836698
24.

A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke.

Boudreau DM, Guzauskas G, Villa KF, Fagan SC, Veenstra DL.

Ann Emerg Med. 2013 Jan;61(1):46-55. doi: 10.1016/j.annemergmed.2012.04.020. Epub 2012 May 24.

25.

The cost-effectiveness of primary stroke centers for acute stroke care.

Guzauskas GF, Boudreau DM, Villa KF, Levine SR, Veenstra DL.

Stroke. 2012 Jun;43(6):1617-23. doi: 10.1161/STROKEAHA.111.648238. Epub 2012 Apr 25.

PMID:
22535277
26.

A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention.

Guzauskas GF, Hughes DA, Bradley SM, Veenstra DL.

Clin Pharmacol Ther. 2012 May;91(5):829-37. doi: 10.1038/clpt.2011.303. Epub 2012 Mar 28.

PMID:
22453194
27.

Microdeletion at 4q21.3 is associated with intellectual disability, dysmorphic facies, hypotonia, and short stature.

Dukes-Rimsky L, Guzauskas GF, Holden KR, Griggs R, Ladd S, Montoya Mdel C, DuPont BR, Srivastava AK.

Am J Med Genet A. 2011 Sep;155A(9):2146-53. doi: 10.1002/ajmg.a.34137. Epub 2011 Aug 10.

28.

Meeting the governance challenges of next-generation biorepository research.

Fullerton SM, Anderson NR, Guzauskas G, Freeman D, Fryer-Edwards K.

Sci Transl Med. 2010 Jan 20;2(15):15cm3. doi: 10.1126/scitranslmed.3000361.

29.

A novel GLRA1 mutation associated with an atypical hyperekplexia phenotype.

Gregory ML, Guzauskas GF, Edgar TS, Clarkson KB, Srivastava AK, Holden KR.

J Child Neurol. 2008 Dec;23(12):1433-8. doi: 10.1177/0883073808320754.

PMID:
19073849
30.

Alterations in CDH15 and KIRREL3 in patients with mild to severe intellectual disability.

Bhalla K, Luo Y, Buchan T, Beachem MA, Guzauskas GF, Ladd S, Bratcher SJ, Schroer RJ, Balsamo J, DuPont BR, Lilien J, Srivastava AK.

Am J Hum Genet. 2008 Dec;83(6):703-13. doi: 10.1016/j.ajhg.2008.10.020. Epub 2008 Nov 13.

31.

tSNP-based identification of allelic loss of gene expression in a patient with a balanced chromosomal rearrangement.

Guzauskas GF, Ukadike K, Rimsky L, Srivastava AK.

Genomics. 2007 Apr;89(4):562-5. Epub 2007 Jan 22.

32.

The duty to re-contact for newly appreciated risk factors: fragile X premutation.

Guzauskas GF, Lebel RR.

J Clin Ethics. 2006 Spring;17(1):46-52. No abstract available.

PMID:
16689113
33.

AGTR2 in brain development and function.

Vervoort VS, Guzauskas G, Archie J, Schwartz CE, Stevenson RE, Srivastava AK.

Am J Med Genet A. 2006 Mar 1;140(5):419-20. No abstract available.

Supplemental Content

Loading ...
Support Center